Business Wire

IDEMIA

5.11.2020 11:02:09 CET | Business Wire | Press release

Share
IDEMIA Partners With Nationwide Building Society, the World’s Largest Building Society, to Issue Recycled Plastic Cards

IDEMIA, the global leader in Augmented Identity, and Nationwide Building Society, the world’s largest building society, both undertake to promote greener financial services. From 2021, new IDEMIA-sourced cards made from recycled plastic will be rolled out in the UK.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201105005086/en/

At a time when environmental issues increasingly take center stage, IDEMIA will join forces with Nationwide Building Society to deliver cards made from recycled PVC that will slash the bank’s carbon footprint without compromising on security or end user convenience.

With Nationwide’s 5.4 million new plastic payment cards every year, this alliance aims to save 35 metric tons of carbon annually - production of one card will save 7 grams of carbon compared to a standard PVC payment card. By using recycled PVC sourced from printing and packaging industrial waste, IDEMIA’s solutions slash plastic waste, which significantly reduces carbon emissions. It also helps to reduce landfill space, energy consumption as well as land and water pollution.

Nationwide will introduce cards made using recycled plastics from early spring next year and is the first high street lender to commit to do so. The environmentally-friendly cards will be issued to current account members first, before “the Society” rolls out the cards across its product range. Nationwide pledges to eliminate single-use plastics by 2025.

This alliance reinforces IDEMIA’s determination to bring about change in the financial services industry. It forms part of GREENPAY™, IDEMIA’s eco-friendly all-embracing package deal for financial institution customers around the world.

IDEMIA’s Executive VP Financial Institutions Amanda Gourbault said: “IDEMIA is proud to be a long term partner of Nationwide Building Society and delighted to support Nationwide’s sustainability goals with IDEMIA’s recycled plastics payment card product. This type of card is manufactured from waste materials and as such significantly reduces plastic waste, one of the most pressing problems of our modern world. Migrating to recycled plastics is also beneficial as it saves energy, limits oil consumption and reduces greenhouse gas emissions, to help mitigate global warming and reduce air pollution. At IDEMIA, we take sustainable development very seriously and we are using our expertise to create and promote more responsible and environmentally friendly solutions through GREENPAY, our portfolio of sustainable solutions for financial institutions and FinTechs . Nationwide’s decision to provide its members with eco-friendly PVC cards from IDEMIA confirms our objective to provide green solutions that help protect our planet – because banking cards shouldn’t cost the earth”.

Claire Tracey, Chief Strategy and Sustainability Officer at Nationwide Building Society added : “We’re proud to be the first high street lender in the UK to offer cards made from recycled plastics. Our members tell us that, despite the tough times right now, they still want to make the world a greener place. Earlier this year we became carbon neutral for energy and emissions for all internal operations and Society vehicles. We’ve also set aside £1 billion for our members to borrow at a special low interest rate if they want to make their homes greener. Today’s news is another step for us in helping the UK to achieve net-zero by 2050 and a significant step in us eliminating single-use plastics by 2025.”

IDEMIA is a leader in innovative solutions that meet user needs in the rapidly changing financial services industry landscape. They offer financial institutions a complete and innovative portfolio of solutions ranging from classic EMV card technologies, eye-catching metal cards, to cutting-edge mobile payment, digital services and innovative online payment security.

About IDEMIA

IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space. Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.

With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.

For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye